NPHCOTCinactive

NUTRA PHARMA CORP

Healthcare·Neurology·Commercial·Boca Raton, FL, United States
NeurologyImmunologyInfectious DiseasePainMusculoskeletal

NUTRA PHARMA CORP (NPHC): 7 pipeline candidates · 2 clinical trials. Updated within the last hour.

9.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.8

D/E -1.04 · 12% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NUTRA PHARMA CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$716K

Cash

—

Quarterly Burn

$328K

Runway

—

Revenue

$27K

Pipeline (7 candidates)

DrugPhase
nyloxinApproved
pet pain-awayApproved
recetPreclinical
rpi-70Preclinical
rpi-78Preclinical
rpi-78mPreclinical
rpi-mnPreclinical
2 clinical trials·CEO: Dr. Michael D. Flax D.D.S., M.S., P.A.

Frequently asked questions

How many drug candidates are in NUTRA PHARMA CORP's pipeline?

NUTRA PHARMA CORP (NPHC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NUTRA PHARMA CORP's lead drug candidate?

NUTRA PHARMA CORP's most advanced tracked candidate is nyloxin (Approved) for Moderate to severe chronic pain.

What is NUTRA PHARMA CORP's market capitalization?

NUTRA PHARMA CORP's market capitalization is approximately $716K.

Who is the CEO of NUTRA PHARMA CORP?

Dr. Michael D. Flax D.D.S., M.S., P.A. is the chief executive officer of NUTRA PHARMA CORP (NPHC).

Get the full picture on NUTRA PHARMA CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar